Oct. 20, 2004
Giving Hookworms the Hook
The Sabin Vaccine Institute, sponsor of research funded by the Bill &
Melinda Gates Foundation on a newly developed vaccine to prevent human
hookworm disease, has signed a memorandum of understanding with federal
and state vaccine production facilities in Brazil for clinical development
of the vaccine, including clinical trials and vaccine manufacturer. Earlier
this month, representatives from the Sabin Institute and The George Washington
University, where the research on the vaccine is underway, visited the
research and production plants affiliated with the government of Brazil.
Brazilian medical practitioners are hopeful the new vaccine will prevent
an ages-old disease endemic in Brazil that is caused by the devastating
intestinal parasite.
This is the best and most substantive international collaboration
Ive ever had in 20 years of work in tropical medicine, said
Peter J. Hotez, professor and chair of the Department of Microbiology
and Tropical Medicine at the GW Medical Center and senior fellow at the
Sabin Institute.
Hotez, who has spent more than 20 years studying hookworm disease and
devising a vaccine to prevent infection, serves as the lead scientist
for the hookworm vaccine trial. His team met with Brazilian scientists
at the Oswaldo Cruz Foundation, a research arm of the Brazilian Ministry
of Health, and with researchers at the Butantan Institute, both of which
operate vaccine-manufacturing plants. Officials from each group signed
the memo of understanding.
According to Hotez, Brazil is like only a few countries in the world having
both high endemic incidence of hookworm and pockets of extreme poverty,
along with a high technology capacity and ability to develop biological
products. These features also would describe such middle income
countries as China, Mexico, India and South Africa, he said. Brazil
is one of the few countries with the technical capacity and intrinsic
interest in the problem because hookworm is a public health threat in
their nation.
The trip was arranged in order to garner the support of the Brazilian
government for its commitment to produce the hookworm vaccine, says Dean
Mason, president of the Sabin Vaccine Institute, who along with Ciro de
Quadros, director of Sabins International Programs, and Maria Elena
Bottazzi, project program manager and GW assistant professor of microbiology
and tropical medicine, also made the trip.
What is remarkable is the openness and cooperation of the government
of Brazil at the highest levels, said Mason, who signed the agreement
on behalf of the Sabin Institute. This is a country where they are
willing to get the vaccine to the needy. The whole idea, if the vaccine
field trials prove successful, is to make the hookworm vaccine available
for those afflicted and the poorest of the poor. No one is looking to
make a commercial profit, but instead we are doing this for the best of
reasons
necessity.
The hookworm vaccine developed by Hotez will soon undergo clinical trials,
so a team of a dozen workers led by project clinical director Jeffrey
Bethony is now assembling baseline data. The team is based in Belo Horizonte,
Brazil, near the rural area impacted by hookworm disease. In just more
than a year, that data and data from safety and tolerability trials in
the United States, will serve as required groundwork for a wider clinical
trial, to ascertain the efficacy and safety of the new vaccine.
Send feedback to: bygeorge@gwu.edu
|
|
|